REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels
← catalyst calendarNCT05669755 · readout in 377 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
7,101actual
Sites
633
Countries
Argentina, Australia, Brazil +22
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-01 | actual | When the study began enrolling |
| Primary completion | 2027-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-13 | estimated | The whole study's end, after follow-up |
| First posted | 2023-01-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cardiovascular Disease
Interventions
- Drug: Cagrilintide
- Drug: Semaglutide
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFTime to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke
measured From baseline (week 0) to end of study (up to 242 weeks or more)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed